Drug Bulletin - October 2001
Help on accessing alternative formats, such
as PDF, MP3 and WAV files, can be obtained in the alternate
format help section.
(98.5 KB)
The Non-Insured Health Benefits (NIHB) Program
provides supplementary
health benefits,prescription and non-prescription drugs, for registered
Indians, and recognized Inuit and Innu throughout Canada.
Additions to the Drug Benefit List (Full Benefits)
(Effective October 1, 2001)
- Eprosartan, tablet, 300mg, 400mg, 600mg (Teveten -
Solvay)
Eprosartan is the sixth angiotension II receptor antagonist in
Canada and has similar efficacy, tolerability and side effect
profile as the others. It is indicated for the treatment of mild
to moderate essential hypertension, alone or concomitantly with
thiazide diuretics. It is normally used in patients in whom treatment
with diuretics or beta blockers is contraindicated or found to
be ineffective or in patients who have experienced side effects
with ACE inhibitors. Other "sartans" covered by NIHB
include candesartan, irbesartan, losartan, telmisartan and valsartan.
- Ethinyl estradiol / norethindrone acetate, tablet,
5mcg / 1mg (FemHRT - Pfizer)
This product delivers a continuous combined estrogen-progestin
combination regimen via the oral route. FemHRT is indicated in
women with an intact uterus for the relief of menopausal and
postmenopausal symptoms in naturally or surgically induced estrogen
deficiency states; for the prevention of osteoporosis in naturally
or surgically induced estrogen deficiency states; for symptomatic
treatment of vulvular and vaginal atrophy associated with menopause.
As this product is more costly than other listed oral hormone
replacement therapy, it should be used when these agents are
not tolerated.
- Estradiol / norethindrone acetate, transdermal patch,
0.51mg / 4.8mg; 0.62mg / 2.7mg (Estalis - Novartis)
Estalis is indicated for the relief of menopausal and postmenopausal
symptoms occurring in naturally or surgically induced estrogen
deficiency states. Estalis is the first combination estrogen/
progestin transdermal patch developed for use in a continuous-wear
dosage regimen. It offers an alternative to the sequential-wear
transdermal patches for postmenopausal women; however, it can
be used in a sequential regimen in combination with an estradiol-only
transdermal delivery system. Estalis should be used only in patients
with an intact uterus. As this product (as well as other transdermal
products) is more costly than oral hormone replacement therapy,
it should be used when oral hormone replacement therapy is contraindicated
or not tolerated.
- Conjugated estrogens, tablet, 0.625mg and medroxyprogesterone
acetate, tablet, 2.5mg (PremPlus - Wyeth-Ayerst)
PremPlus provides conjugated estrogens and medroxyprogesterone
as separate tablets in compliance packaging. PremPlus is indicated
in women with an intact uterus for the relief of menopausal and
postmenopausal symptoms in naturally or surgically induced estrogen
deficiency states; for the prevention of osteoporosis in naturally
or surgically induced estrogen deficiency states; for treatment
of vulvular and vaginal atrophy associated with menopause.
- Levonorgestrel, intrauterine device, 52mg (Mirena -
Berlex)
Mirena is a levonorgestrel releasing intrauterine system, indicated
for contraception. It is effective for up to 5 years. It is not
the contraceptive method of first choice for young nulligravid
women.
- Exemestane, tablet, 25mg (Aromasin - Pharmacia)
Exemestane is an oral irreversible aromatase inhibitor. It is
indicated for the hormonal treatment of advanced breast cancer
in women with natural or artificially induced postmenopausal
status whose disease has progressed following antiestrogen therapy.
New Limited Use Benefits
(Effective October 1, 2001)
Pioglitazone, tablet, 15mg, 30mg, 45mg (Actos - Eli Lilly)
Pioglitazone, the second "glitazone" available on the
Canadian market, is indicated as monotherapy in patients with type
2 diabetes mellitus who are not controlled by diet and exercise
alone. The cost of both, pioglitazone and rosiglitazone, is significantly
greater than that of other listed oral hypoglycemic drugs. The
criteria for coverage are: for treatment of type 2 diabetic patients
who are not adequately controlled by or are intolerant of metformin
and sulfonylureas or for whom these products are contraindicated.
CORRECTION OF CRITERIA
Please note that the criteria for coverage for
Ciprofloxacin/ hydrocortisone ear drops, 2mg/ 10mg per
ml (Cipro HC Otic-Alcon) are:
- failure to respond to other listed antibiotics
- contraindications to other listed antibiotics
Chloral Hydrate Status Changing from Full Benefit to Exception Drug
(Effective November 1, 2001)
Effective November 1, 2001, chloral hydrate will
no longer be available as a full benefit. It will be available
as an exception drug with requests for coverage considered on an
individual basis.
A review of the utilization trends of chloral hydrate by the NIHB
Program indicates that a small number of clients are receiving
large numbers of prescriptions and large quantities of chloral
hydrate per prescription. According to the product monograph in
the Compendium of Pharmaceuticals and Specialties (CPS) 2001, chloral
hydrate should be use as a hypnotic for short term use only, usually
2 to 7 days. Because of the propensity of chloral hydrate for rapid
development of tolerance, fatalities by overdose, development of
physical and psychological dependence, withdrawal syndromes and
significant drug interactions, the NIHB Program is changing the
status of this drug from a full benefit to one that requires prior
approval.
Note: Sudden withdrawal after prolonged use may
result in hallucinations and symptoms similar to delirium tremens.
This can be serious and even fatal. It is recommended that to avoid
these types of reactions, the dose of chloral hydrate should be
reduced gradually over several days. If additional supply is required,
the Drug Exception Centre should be contacted to obtain prior approval
for this drug. An emergency supply can be provided when timely
access to the Centre is not possible (e. g. statutory holidays).
|